01Clinical context
What is the rationale?
A defined rationale, medicines, organ function, previous reactions and proportionate alternatives are reviewed.
NAD+ Infusion · IV Supportive Treatments · Istanbul
NAD+ Infusion · IV Supportive Treatments · Istanbul
NAD+ Infusion
NAD+ biochemistry, oral supplements and IV NAD+ do not share one clinical evidence base. A named care method, ingredient or infusion is not a diagnosis and does not establish personal suitability.
Online information cannot diagnose, select an IV product, formula, dose, rate or laboratory protocol, or promise an outcome. Final decisions require an in-person medical assessment.
Clinical Orientation
Finding · identity · evidence · safety
Four questions precede a personal plan.
The sequence prevents a category name from becoming an automatic treatment recommendation.
02Identity
What exactly is proposed?
Product identity, manufacture, purity, stability, licence, compatibility and sterile administration must be established.
03Evidence
What does the evidence support?
Clinical evidence for IV NAD+ remains limited and does not support guaranteed energy, cognition, addiction treatment, longevity or cellular restoration.
04Safety
When should it stop?
Stop for chest symptoms, breathing difficulty, severe nausea, neurological symptoms, swelling or a significant infusion-site reaction.
What is an NAD+ Infusion?
NAD+ · Coenzyme · Intravenous administration
NAD+ is biologically important — the infusion still requires clinical assessment.
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme involved in redox reactions and energy metabolism. The intravenous route changes delivery, but does not prove improvement in energy, cognition, recovery or ageing processes.
What an NAD+ Infusion can do
- Be assessed as a possible option only for a specifically defined medical reason
- Be documented with product, concentration, dilution and infusion rate
- Be administered while circulation, venous access and subjective symptoms are observed
- Be reassessed against a predefined clinical endpoint and tolerance
What an NAD+ Infusion cannot do
- Translate the cellular function of NAD+ into a guaranteed treatment effect
- Promise energy, anti-ageing, concentration, detoxification or faster recovery
- Treat fatigue, sleep problems or reduced performance without investigating their cause
- Replace product quality, sterile manufacture, alternatives or the option not to proceed
A plausible metabolic mechanism, a changed laboratory value or a subjective impression does not automatically prove patient-relevant benefit. Robust clinical data and an appropriate personal aim are required.
Medical Suitability
Rationale and organ context before venous access
Five checks come before selection.
History, examination, current treatment, contraindications and a proportionate alternative are reviewed together.
- 01
Clarify the problem
A defined rationale, medicines, organ function, previous reactions and proportionate alternatives are reviewed.
- 02
Review current treatment
Medicines, allergies, previous procedures or infusions and relevant reactions are considered.
- 03
Identify the exact option
Product identity, manufacture, purity, stability, licence, compatibility and sterile administration must be established.
- 04
Compare alternatives
No infusion, diagnosis-led evaluation, nutrition, sleep or other established care as appropriate
- 05
Plan follow-up
Stop for chest symptoms, breathing difficulty, severe nausea, neurological symptoms, swelling or a significant infusion-site reaction.
Infusion Safety Path
Before · during · after
Safety depends on a complete, documented chain.
Product identity, manufacture, purity, stability, licence, compatibility and sterile administration must be established.
01Before
Confirm rationale and product identity
A defined rationale, medicines, organ function, previous reactions and proportionate alternatives are reviewed.
- Review history and examination
- Check contraindications
- Keep alternatives open
02During
Control preparation and administration
Product identity, manufacture, purity, stability, licence, compatibility and sterile administration must be established.
- Maintain traceability
- Monitor tolerance
- Stop when safety changes
03After
Separate expected response from harm
Stop for chest symptoms, breathing difficulty, severe nausea, neurological symptoms, swelling or a significant infusion-site reaction.
- Record observations
- Explain warning signs
- Provide a review route
No public mixture formula, dose, dilution, rate, volume, laboratory panel or infusion schedule is provided.
Evidence and Limits
Method-, product- and indication-specific
Biology or popularity is not proof of clinical benefit.
Clinical evidence for IV NAD+ remains limited and does not support guaranteed energy, cognition, addiction treatment, longevity or cellular restoration.
Keep the indication exact
Evidence in one diagnosis or deficiency does not establish a general effect.
Keep the intervention exact
Product identity, manufacture, purity, stability, licence, compatibility and sterile administration must be established.
Keep endpoints separate
Symptoms, photographs, laboratory values and patient-reported outcomes are not interchangeable.
Retain uncertainty
No energy, cognitive, addiction, longevity, anti-ageing or cellular-renewal guarantee is made.
Manufacturer information may identify a product and instructions, but it is not treated as independent evidence of a general class effect.
Individual Plan
No automatic series
One aim, one infusion, one reassessment.
Repetition does not follow from a package, but only from tolerance, reviewable benefit and renewed assessment.
Baseline
Document the symptom, functional aim and possible cause.
Single step
Record the product, dilution, rate and stopping rules.
Two assessments
Record early tolerance and the later endpoint separately.
Decide again
Reassess only when there is justified benefit; otherwise stop.
Course and Follow-Up
Expected response · complication · reassessment
Repetition is never automatic.
Tolerance and the agreed clinical endpoint are reviewed separately before any further intervention.
- 01Before
Baseline
Record the starting clinical context and intended endpoint.
- 02Same day
Immediate review
Observe tolerance and unexpected reactions.
- 03Later
Clinical review
Compare the relevant finding without automatic attribution.
- 04Decision
Continue, change or stop
Stop for chest symptoms, breathing difficulty, severe nausea, neurological symptoms, swelling or a significant infusion-site reaction.
Risks and Alternatives
Sterile quality and systemic reactions
Product and infusion reaction belong in the same safety plan.
Severe chills, shaking, vomiting and fatigue have been reported with injectable NAD+ products; product quality and sterile manufacture are therefore central.
01Product
Trace the preparation
Identity, source, concentration, batch, storage, expiry and sterile preparation are documented.
02Local
Check the access
Pain, swelling, redness or fluid outside the vein is assessed immediately.
03Reaction
Systemic signs
Nausea, vomiting, chills, shaking or circulatory change leads to stopping and assessment.
04Emergency
Urgent help
Breathing difficulty, chest pain, altered consciousness or severe neurological symptoms need immediate help.
Reports do not establish the frequency of every reaction, but they show why product checks and monitoring are necessary. Acute severe symptoms receive immediate local medical care.
Istanbul and Follow-Up
Assessment and review must travel together
International care needs a workable safety route.
Travel does not shorten observation or remove the need for local medical access.
01
Organise the question
History and existing records prepare discussion without confirming treatment.
02
Assess in person
A defined rationale, medicines, organ function, previous reactions and proportionate alternatives are reviewed.
03
Keep exact records
Product identity, manufacture, purity, stability, licence, compatibility and sterile administration must be established.
04
Plan escalation
Stop for chest symptoms, breathing difficulty, severe nausea, neurological symptoms, swelling or a significant infusion-site reaction.
The Doctor Aslan Approach
Medical position
Cellular relevance is not yet a personal indication.
Dr İsmail Aslan separates the biological function of NAD+ from the clinical question of whether intravenous use is reasonable for a particular person. A measurable aim, investigation of causes, product quality, monitored tolerance and the option not to proceed determine the decision.
Cause before shortcut
Non-specific symptoms are not explained by a trend molecule.
Evidence before promise
Cell function and biomarkers do not replace proof of patient-relevant benefit.
Tolerance before speed
Rate and symptoms are actively monitored and documented.
Reassessment before a series
Another infusion is not derived automatically from a package.
Medical responsibility: Dr İsmail AslanMedical review: 24 August 2026General patient information about NAD+ Infusion; no personal prescription or outcome guarantee
Frequently Asked Questions
Short and clear
Questions commonly asked before a decision.
These answers provide general orientation and do not replace personal diagnosis or treatment planning.
01What is NAD+, and what does its cellular role not prove?+
NAD+ is an endogenous coenzyme involved in redox reactions and energy metabolism. This central cellular role does not prove that intravenous NAD+ improves non-specific symptoms, changes ageing processes or produces clinically relevant benefit. Biological mechanism, biomarker and patient-relevant benefit must be assessed separately.
02Is an NAD+ infusion scientifically established for energy or anti-ageing?+
Available clinical evidence is currently insufficient for a reliable general claim about energy, anti-ageing, cognition or wellness. Small or non-randomised studies and biomarker changes cannot establish broad effectiveness. Neither an outcome nor a fixed infusion series is therefore inferred from biological plausibility.
03Why are infusion rate and symptoms monitored closely?+
Symptoms may occur during intravenous administration and may require a pause, slower rate or stopping. Nausea, vomiting, pressure or abdominal symptoms, chills, shaking and circulatory changes are not accepted as a necessary part of treatment; they are documented and medically assessed.
04Why are active-ingredient quality and sterile preparation critical?+
An injectable product bypasses natural protective barriers. Identity, concentration, source, batch, expiry, dilution, compatibility, storage and sterile preparation must therefore be traceable. Unsuitable starting materials and microbial or endotoxin contamination can cause severe systemic reactions and rule out an unclear application.
Next Step
Define the question · verify the option · compare alternatives